Congenital Hyperinsulinism Market

Congenital hyperinsulinism (CHI) is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent occurrences of low blood sugar (hypoglycemia). In infants and young children, these occurrences are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.

Congenital Hyperinsulinism Market contains market size and forecasts of Congenital Hyperinsulinism in Global, including the following market information:

• Global Congenital Hyperinsulinism Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Congenital Hyperinsulinism market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Surgery Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Congenital Hyperinsulinism include IVAX Pharmaceuticals, Teva Pharmaceuticals, Zealand Pharma, Rezolute, Xeris Pharmaceuticals, Eiger BioPharmaceuticals, AmideBio and Recordati, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Congenital Hyperinsulinism companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Congenital Hyperinsulinism Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Congenital Hyperinsulinism Market Segment Percentages, by Type, 2021 (%)

• Surgery
• Medication
• Others

Global Congenital Hyperinsulinism Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Congenital Hyperinsulinism Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Others

Global Congenital Hyperinsulinism Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Congenital Hyperinsulinism Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Congenital Hyperinsulinism revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Congenital Hyperinsulinism revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• IVAX Pharmaceuticals
• Teva Pharmaceuticals
• Zealand Pharma
• Rezolute
• Xeris Pharmaceuticals
• Eiger BioPharmaceuticals
• AmideBio
• Recordati